On 4/17/19 KCI Holdings filed for a $100 million IPO. KCI is a leading medical technology company focused on advanced wound care and specialty surgical applications. The initial filing did not... read more
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced on 4/17/19 the... read more
On 4/16/19, Flagship Pioneering, unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief executive officer, and member of the board of directors. Kintai is... read more
Cortexyme has filed for an $86 million IPO. The company is developing treatments for neurodegenerative diseases based on the discovery of pathogenic bacteria in the brains of Alzheimer's patients... read more
Early stage biotech, Axcella Health, has filed for an $86 million IPO. The initial filing documents do not provide the number of shares in the offering or the expected price range. The company has... read more
MaaT Pharma announced on 4/9/19 that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980).... read more
On 4/8/19 researchers from Azitra, Inc., in collaboration withindependent, nonprofit biomedical research institutionThe Jackson Laboratory (JAX), announced they have demonstrated the feasibility... read more
OZ, a global consulting company enhancing customer experiences through digital innovation, recently launched a first-of-its-kind application that brings an augmented reality (AR) environment to... read more
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, Provided the results of its first human study on 4/8/19.
The study was primarily undertaken to show... read more
Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, updated its S-1 Filing. The company is proposing... read more
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) announced on 4/5/19 that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid... read more
C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage, today announced that the United... read more
Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, have signed an agreement to establish a 50/50 joint venture to pioneer... read more
Just a month ago, Silk Road filed for its IPO with an expected maximum of $86 million. The company just amended the filing with a new expected maximum of $138 million. The company intends to trade... read more
Cambridge Innovation Capital plc (CIC), the venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem, has completed a... read more
Enterome SA announced on 3/27/19 that it will present data on its innovative microbiome-based approach for the development of therapeutic peptide cancer vaccines for the first time in a poster at... read more